Patents-Review.com
ClassID:

20132 ⎘

A61K9/2886 - CPC Classification

Classification description:

Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Recent Application in this class:
#1
20260034114
2026-02-05

ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE

 #2
20260027062
2026-01-29

IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS

 #3
20260000697
2026-01-01

COMBINATION FORMULATION OF CEDAZURIDINE

 #4
20250381193
2025-12-18

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile

 #5
20250375382
2025-12-11

ORAL PEPTIDE DRUG STRUCTURE AND MANUFACTURING METHOD THEREOF

 #6
20250375381
2025-12-11

Compositions and methods for treating bile acid malabsorption

 #7
20250302847
2025-10-02

PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF

 #8
20250295597
2025-09-25

DOSAGE FORM WITH DRUG RELEASE AT PH 3 TO 6 USING DOUBLE COATING SYSTEM WITH AT LEAST ONE RELEASE ACCELERATION AGENT

 #9
20250248941
2025-08-07

COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINE

 #10
20250222082
2025-07-10

PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS

 #11
20250186353
2025-06-12

ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE

 #12
20250161222
2025-05-22

ENTERIC COATED TABLET

 #13
20250144031
2025-05-08

COMPOSITION FOR TREATING SPINAL MUSCULAR ATROPHY

 #14
20250114330
2025-04-10

(3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION

 #15
20250090456
2025-03-20

SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONS

 #16
20250090455
2025-03-20

SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS

 #17
20250082661
2025-03-13

ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

 #18
20250073301
2025-03-06

Delayed Release Compositions of Linaclotide

 #19
20250073203
2025-03-06

IMMUNOSUPPRESSANT FORMULATION

 #20
20250057771
2025-02-20

ROOM TEMPERATURE STABLE ORAL CALCITONIN FORMULATION

 #21
20250049743
2025-02-13

METHOD OF PRODUCING AN ORAL OSMOTIC PHARMACEUTICAL DELIVERY SYSTEM AND A PHARMACEUTICAL BATCH PRODUCED USING THE SAME

 #22
20250000804
2025-01-02

COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS

 #23
20240424003
2024-12-26

PHARMACEUTICAL COMPOSITIONS FOR MINOCYCLINE

 #24
20240398904
2024-12-05

FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS

 #25
20240342097
2024-10-17

SOLID ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING COMPLEX MONOLITHIC MATRICES FOR CHRONOTROPIC ADMINISTRATION OF MEDICAMENTS IN THE GASTROINTESTINAL TRACT

 #26
20240342096
2024-10-17

MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS

 #27
20240299305
2024-09-12

Extended release compositions comprising pyridostigmine

 #28
20240293328
2024-09-05

Solid Dosage Form

 #29
20240285539
2024-08-29

PROTECTIVE COATING FOR MOISTURE SENSITIVE PHARMACEUTICAL COMPOSITIONS

 #30
20240207275
2024-06-27

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

 #31
20240207193
2024-06-27

CHEMICAL COMPOSITION FOR ENTERIC DRUG DELIVERY

 #32
20240181020
2024-06-06

TREATMENT OF HYPOPARATHYROIDISM

 #33
20240139110
2024-05-02

SLEEP-REGULATING TABLET ALLOWING RELEASE BY STAGES AND PREPARATION METHOD THEREOF

 #34
20240115493
2024-04-11

SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONS

 #35
20240075094
2024-03-07

Low-Dose Stable Formulations of Linaclotide

 #36
20240058273
2024-02-22

METHOD FOR PREPARING PHARMACEUTICAL FORMULATION OF TABLET CONTAINING TRIZOLOPYRAZINE DERIVATIVE AS AN ACTIVE INGREDIENT

 #37
20240050464
2024-02-15

Therapeutic composition and methods

 #38
20240024249
2024-01-25

ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG

 #39
20230414542
2023-12-28

ORALLY DISPERSIBLE COMPOUND CONTAINING AN ESTER OR SALT OF N-BUTYRIC ACID AND PROCESS FOR PRODUCTION

 #40
20230398173
2023-12-14

Delayed Release Compositions of Linaclotide

 #41
20230381203
2023-11-30

Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use

 #42
20230372358
2023-11-23

Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

 #43
20230372250
2023-11-23

ENTERIC COATED TABLET

 #44
20230372241
2023-11-23

SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS

 #45
20230364107
2023-11-16

Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

 #46
20230355689
2023-11-09

SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES

 #47
20230355591
2023-11-09

Pharmaceutical composition and use thereof

 #48
20230293445
2023-09-21

IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS

 #49
20230277466
2023-09-07

INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS

 #50
20230263735
2023-08-24

FILM COATED TABLET

 #51
20230255996
2023-08-17

Oral formulations of cytidine analogs and methods of use thereof

 #52
20230248656
2023-08-10

Extended release compositions comprising pyridostigmine

 #53
20230241086
2023-08-03

ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

 #54
20230218512
2023-07-13

Fast Disintegrating Cannabinoid Tablets

 #55
20230158004
2023-05-25

ENTERIC-COATED PREPARATION COMPRISING PIRFENIDONE HAVING IMPROVED SAFETY AND STABILITY, AND METHOD FOR PREPARING SAME

 #56
20230142270
2023-05-11

Delayed Release Compositions of Linaclotide

 #57
20230135608
2023-05-04

PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE AS AN ACTIVE INGREDIENT PROVIDES A SPECIFIC PHARMACOKINETIC PARAMETER

 #58
20230120670
2023-04-20

Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

 #59
20230088829
2023-03-23

BIOAVAILABLE POLYAMINES

 #60
20230036151
2023-02-02

ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF

 #61
20230000780
2023-01-05

DOSAGE FORM COMPRISING AN ALKALINE AGENT AND AN ENTERIC COATING LAYER

 #62
20230000779
2023-01-05

Room temperature stable oral calcitonin formulation

 #63
20220409545
2022-12-29

Oral dosage form of ticagrelor and preparation method thereof

 #64
20220387443
2022-12-08

RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN INHIBITOR COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF RSV DISEASES USING THE SAME

 #65
20220387442
2022-12-08

Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

 #66
20220354799
2022-11-10

Solid oral dosage form of irinotecan for the treatment of cancer

 #67
20220331256
2022-10-20

PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES

 #68
20220331255
2022-10-20

Solid Dosage Form

 #69
20220323413
2022-10-13

(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #70
20220288056
2022-09-15

PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE ORAL SOLID TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF

 #71
20220202795
2022-06-30

PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE

 #72
20220202762
2022-06-30

Benzonatate modified release solid tablets and capsules

 #73
20220192998
2022-06-23

NEW DELIVERY SYSTEM FOR POLYUNSATURATED FATTY ACIDS

 #74
20220125732
2022-04-28

IBUPROFEN AND FAMOTIDINE TABLET

 #75
20220110879
2022-04-14

Immediate release abuse-deterrent granulated dosage forms

 #76
20220105118
2022-04-07

ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

 #77
20220096386
2022-03-31

Extended release compositions comprising pyridostigmine

 #78
20220079964
2022-03-17

Oral formulations of cytidine analogs and methods of use thereof

 #79
20220079884
2022-03-17

PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX

 #80
20220047560
2022-02-17

FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF

 #81
20220031802
2022-02-03

Low-Dose Stable Formulations of Linaclotide

 #82
20220023222
2022-01-27

METHOD OF PRODUCING A DELAYED RELEASE DRUG FORMULATION

 #83
20220016039
2022-01-20

SOLID ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING COMPLEX MONOLITHIC MATRICES FOR CHRONOTROPIC ADMINISTRATION OF MEDICAMENTS IN THE GASTROINTESTINAL TRACT

 #84
20210393535
2021-12-23

Rapidly disintegrating gelatinous coated tablets

 #85
20210369743
2021-12-02

Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use

 #86
20210353649
2021-11-18

PHARMACEUTICAL COMPOSITIONS FOR MINOCYCLINE

 #87
20210353558
2021-11-18

Composition and method for treating neurological disease

 #88
20210353535
2021-11-18

Orally disintegrating compositions

 #89
20210346286
2021-11-11

Chewable tablet and method of preparing the same

 #90
20210330657
2021-10-28

Extended release compositions comprising trihexyphenidyl

 #91
20210322437
2021-10-21

ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS

 #92
20210322429
2021-10-21

STABILIZED FORMULATIONS OF CNS COMPOUNDS

 #93
20210283062
2021-09-16

Controlled release dosage form with enhanced pharmacokinetics

 #94
20210228525
2021-07-29

Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects

 #95
20210220281
2021-07-22

ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE

 #96
20210177766
2021-06-17

Delivery system

 #97
20210177748
2021-06-17

Fast disintegrating cannabinoid tablets

 #98
20210161860
2021-06-03

IMMUNOSUPPRESSANT FORMULATION

 #99
20210154180
2021-05-27

FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

 #100
20210145755
2021-05-20

ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF

 #101
20210113567
2021-04-22

Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

 #102
20210093610
2021-04-01

(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #103
20210093577
2021-04-01

ENTERIC COATED TABLET

 #104
20210085617
2021-03-25

Immediate release abuse-deterrent granulated dosage forms

 #105
20210069117
2021-03-11

Extended release compositions comprising pyridostigmine

 #106
20210038524
2021-02-11

Extended release compositions comprising trihexyphenidyl

 #107
20210038523
2021-02-11

Extended release compositions comprising trihexyphenidyl

 #108
20210030687
2021-02-04

Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate

 #109
20210030686
2021-02-04

Intestinal alkaline phosphatase formulations

 #110
20200375948
2020-12-03

(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #111
20200375947
2020-12-03

(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #112
20200352983
2020-11-12

Bioavailable polyamines

 #113
20200352866
2020-11-12

Delivery system

 #114
20200330392
2020-10-22

BIMODAL RELEASE ONDANSETRON TABLETS AND METHODS OF TREATING NAUSEA AND VOMITING

 #115
20200323781
2020-10-15

Anti-methanogenic compositions and uses thereof

 #116
20200316099
2020-10-08

ISOTOPOLOGUES OF 5-AZACYTIDINE

 #117
20200261372
2020-08-20

Extended release compositions comprising trihexyphenidyl

 #118
20200253933
2020-08-13

METHODS FOR TREATING DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME

 #119
20200246271
2020-08-06

Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof

 #120
20200230063
2020-07-23

Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

 #121
20200214987
2020-07-09

Delayed release drug formulation

 #122
20200214986
2020-07-09

Rapidly disintegrating gelatinous coated tablets

 #123
20200163926
2020-05-28

Benzonatate modified release solid tablets and capsules

 #124
20200146992
2020-05-14

Milrinone controlled-release formulation

 #125
20200138913
2020-05-07

Formulations for oral administration of active agents

 #126
20200129439
2020-04-30

Controlled release dosage form with enhanced pharmacokinetics

 #127
20200101095
2020-04-02

Isotopologues of 5-azacytidine

 #128
20200101053
2020-04-02

Method of treating heart failure with preserved ejection fraction by administering milrinone

 #129
20200093750
2020-03-26

COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS

 #130
20200085792
2020-03-19

Formulations of cycloserine compounds and applications thereof

 #131
20200060964
2020-02-27

SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS

 #132
20200046670
2020-02-13

Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof

 #133
20200038476
2020-02-06

Low-Dose Stable Formulations of Linaclotide

 #134
20200000730
2020-01-02

SOLID PREPARATION

 #135
20190381007
2019-12-19

(3AR)-1,3A,8-trimethyl-1,2,3,3A,8,8A-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #136
20190374473
2019-12-12

Extended release compositions comprising pyridostigmine

 #137
20190358164
2019-11-28

ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS

 #138
20190328885
2019-10-31

Anti-methanogenic compositions and uses thereof

 #139
20190328705
2019-10-31

IMMUNOSUPPRESSANT FORMULATION

 #140
20190328675
2019-10-31

Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

 #141
20190314286
2019-10-17

Acidifying coatings and disintegration-resistant substrates coated therewith

 #142
20190307713
2019-10-10

COMBINATIONS OF DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION

 #143
20190282508
2019-09-19

EXTENDED RELEASE DRUG FORMULATION WITH OVERDOSE PROTECTION AND ABUSE DETERRENCE

 #144
20190275153
2019-09-12

Compositions and methods for reducing overdose

 #145
20190262352
2019-08-29

Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs

 #146
20190240209
2019-08-08

Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof

 #147
20190231844
2019-08-01

ORAL APPLICATION OF THIOPEPTCIN

 #148
20190231803
2019-08-01

Isotopologues of 5-azacytidine

 #149
20190231784
2019-08-01

MODIFIED RELEASE FORMULATIONS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

 #150
20190231699
2019-08-01

Controlled-release solid dosage forms of mesalamine

 #151
20190209480
2019-07-11

PHARMACEUTICAL COMPOSITIONS CONFIGURED TO DETER DOSAGE FORM SPLITTING

 #152
20190201354
2019-07-04

COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT

 #153
20190201348
2019-07-04

5-aminosalicylic acid capsule formulation

 #154
20190201324
2019-07-04

INJECTABLE SUSTAINED RELEASE DELIVERY DEVICES

 #155
20190192442
2019-06-27

Room temperature stable oral calcitonin formulation

 #156
20190167654
2019-06-06

Dose-dumping resistant controlled release dosage form

 #157
20190134081
2019-05-09

COMPOSITION FOR THE TREATMENT OF DISEASE

 #158
20190133961
2019-05-09

Immediate release abuse-deterrent granulated dosage forms

 #159
20190117723
2019-04-25

COMPOSITIONS BASED ON PLANT EXTRACTS FOR INHIBITION OF THE 5-ALPHA REDUCTASE

 #160
20190111011
2019-04-18

Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

 #161
20190105275
2019-04-11

Oral pharmaceutical compositions of mesalazine

 #162
20190091156
2019-03-28

Milrinone controlled-release formulation

 #163
20190091146
2019-03-28

Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate

 #164
20190076363
2019-03-14

Controlled release delivery device comprising an organosol coat

 #165
20190070121
2019-03-07

Controlled release dosage form with enhanced pharmacokinetics

 #166
20190060345
2019-02-28

PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS

 #167
20190060323
2019-02-28

Stabilized formulations of CNS compounds

 #168
20190046451
2019-02-14

CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE FORMULATIONS AND USE THEREOF

 #169
20190022014
2019-01-24

Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate

 #170
20190015345
2019-01-17

ENTERIC COATED TABLET

 #171
20190008892
2019-01-10

Bioavailable polyamines

 #172
20190008768
2019-01-10

Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate

 #173
20180369153
2018-12-27

Solid oral dosage form of irinotecan for the treatment of cancer

 #174
20180369152
2018-12-27

Rapidly disintegrating gelatinous coated tablets

 #175
20180344802
2018-12-06

Pharmaceutical formulation for bedwetting and method of use thereof

 #176
20180325826
2018-11-15

Uses of milrinone controlled-release formulation

 #177
20180325825
2018-11-15

GEMCABENE COMBINATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE

 #178
20180311216
2018-11-01

Pharmaceutical Composition Comprising Deferasirox

 #179
20180311187
2018-11-01

Oral amphetamine composition

 #180
20180296526
2018-10-18

Pharmaceutical composition containing an arylalkylamine compound

 #181
20180289816
2018-10-11

Anti-methanogenic compositions and uses thereof

 #182
20180264019
2018-09-20

Composition, device and method for delayed and sustained release of brain energy molecules

 #183
20180256515
2018-09-13

ORAL AMPHETAMINE COMPOSITION

 #184
20180221360
2018-08-09

Dose-dumping resistant controlled release dosage form

 #185
20180221285
2018-08-09

ORAL FORMULATIONS OF DEFERASIROX

 #186
20180221284
2018-08-09

PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX

 #187
20180214424
2018-08-02

PHARMACEUTICAL COMPOSITIONS COMPRISING 40-O-(2-HYDROXY)ETHYL-RAPAMYCIN

 #188
20180200221
2018-07-19

BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES

 #189
20180193274
2018-07-12

COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY

 #190
20180193271
2018-07-12

Oral pharmaceutical dosage form for the delivery of a peptide and/or protein

 #191
20180153916
2018-06-07

Isotopologues of 5-azacytidine

 #192
20180153845
2018-06-07

Pharmaceutical bead formulations comprising dimethyl fumarate

 #193
20180133177
2018-05-17

Treatment of NASH with Gemcabene

 #194
20180116961
2018-05-03

Stimulant abuse-deterrent compositions

 #195
20180036250
2018-02-08

Solid preparation

 #196
20180028452
2018-02-01

ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS

 #197
20180021272
2018-01-25

Formulations for oral administration of active agents

 #198
20180008562
2018-01-11

Oral dosage form containing a fast release exterior coating

 #199
20180000792
2018-01-04

MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME

 #200
20170360767
2017-12-21

MULTI-LAYER NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION

 #201
20170348292
2017-12-07

Method of treating heart failure with preserved ejection fraction by administering milrinone

 #202
20170326073
2017-11-16

JANUS NANOPARTICLE AND METHOD FOR PRODUCING THE SAME

 #203
20170319617
2017-11-09

COMPOSITION FOR THE TREATMENT OF DISEASE

 #204
20170304266
2017-10-26

(3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

 #205
20170304211
2017-10-26

Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol

 #206
20170296799
2017-10-19

INTEGRATED INGESTIBLE EVENT MARKER SYSTEM WITH PHARMACEUTICAL PRODUCT

 #207
20170273946
2017-09-28

EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS

 #208
20170266117
2017-09-21

Delayed release drug formulation

 #209
20170258912
2017-09-14

Compositions and methods for reducing overdose

 #210
20170258768
2017-09-14

Compositions, methods and kits for treating diarrhea-predominant irritable bowel syndrome

 #211
20170231988
2017-08-17

Pharmaceutical composition of rosuvastatin calcium

 #212
20170196816
2017-07-13

LASER-PRINTABLE TABLET, AND METHOD FOR MANUFACTURING THE SAME

 #213
20170189340
2017-07-06

ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS

 #214
20170157056
2017-06-08

ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF

 #215
20170143637
2017-05-25

Immediate release abuse-deterrent granulated dosage forms

 #216
20170119664
2017-05-04

CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY

 #217
20170112770
2017-04-27

Controlled release delivery device comprising an organosol coat

 #218
20170079925
2017-03-23

Compositions and methods for reducing overdose

 #219
20170079924
2017-03-23

Compositions and methods for reducing overdose

 #220
20170049774
2017-02-23

SUSTAINED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB

 #221
20170042806
2017-02-16

ORALLY DISINTEGRATING COMPOSITIONS

 #222
20170035698
2017-02-09

Delayed release drug formulation

 #223
20170020920
2017-01-26

High-loading, controlled-release magnesium oral dosage forms and methods for making and using same

 #224
20170014347
2017-01-19

Dry coated tablet

 #225
20160361339
2016-12-15

Pharmacokinetics of S-adenosylmethionine formulations

 #226
20160354356
2016-12-08

Orally disintegrating compositions

 #227
20160331692
2016-11-17

Solid oral dosage form of irinotecan for the treatment of cancer

 #228
20160331690
2016-11-17

Coated solid dosage forms

 #229
20160317457
2016-11-03

Immediate release abuse-deterrent granulated dosage forms

 #230
20160317456
2016-11-03

PHARMACEUTICAL COMPOSITIONS

 #231
20160310559
2016-10-27

Delayed Release Compositions of Linaclotide

 #232
20160310419
2016-10-27

Controlled release dosage form for once daily administration of dimethyl fumarate

 #233
20160296537
2016-10-13

Pharmaceutical compositions for minocycline

 #234
20160287520
2016-10-06

Multilayer solid pharmaceutical dosage forms

 #235
20160250232
2016-09-01

Delayed release drug formulation

 #236
20160213620
2016-07-28

NOVEL TABLET DOSAGE FORM

 #237
20160199341
2016-07-14

Benzonatate modified release solid tablets and capsules

 #238
20160199300
2016-07-14

Carbidopa/levodopa gastroretentive drug delivery

 #239
20160193154
2016-07-07

Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating

 #240
20160175385
2016-06-23

Pharmaceutical formulation for bedwetting and method of use thereof

 #241
20160175257
2016-06-23

SOLID ORAL DOSAGE FORM OF METHYLPHENIDATE OR SALTS THEREOF

 #242
20160120900
2016-05-05

Composition for the oral administration of magnesium, in association with a composition for treating type 2 diabetes or the complications thereof

 #243
20160113879
2016-04-28

Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof

 #244
20160051578
2016-02-25

Composition for the treatment of disease

 #245
20160051479
2016-02-25

Rapidly disintegrating gelatinous coated tablets

 #246
20160045604
2016-02-18

Anti-methanogenic compositions and uses thereof

 #247
20160008312
2016-01-14

Benzonatate modified release solid tablets and capsules

 #248
20160008288
2016-01-14

Controlled release compositions

 #249
20150374664
2015-12-31

Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3 b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration

 #250
20150374632
2015-12-31

ENTERIC COATED TABLET

 #251
20150335599
2015-11-26

High-loading, controlled-release magnesium oral dosage forms and methods for making and using same

 #252
20150297543
2015-10-22

Pharmaceutical compositions for the coordinated delivery of NSAIDs

 #253
20150258029
2015-09-17

Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

 #254
20150250734
2015-09-10

Stable pharmaceutical compositions of saxagliptin or salts thereof

 #255
20150231084
2015-08-20

Osmotic floating tablets

 #256
20150209298
2015-07-30

Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol

 #257
20150202147
2015-07-23

Modified release formulations of a bupropion salt

 #258
20150190348
2015-07-09

Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol

 #259
20150150816
2015-06-04

Drug formulations having reduced abuse potential

 #260
20150132380
2015-05-14

Delayed release drug formulation

 #261
20150125525
2015-05-07

Delayed release drug formulation

 #262
20150110839
2015-04-23

High-loading, controlled-release magnesium oral dosage forms and methods for making and using same

 #263
20150086629
2015-03-26

Stabilized formulations of CNS compounds

 #264
20150079170
2015-03-19

Tablet dosage form

 #265
20150071998
2015-03-12

Abuse resistant forms of immediate release oxymorphone, method of use and method of making

 #266
20150071995
2015-03-12

Abuse resistant forms of extended release hydrocodone, method of use and method of making

 #267
20150064246
2015-03-05

Abuse resistant forms of extended release oxymorphone, method of use and method of making

 #268
20150064245
2015-03-05

Abuse resistant forms of immediate release hydromorphone, method of use and method of making

 #269
20150056275
2015-02-26

Controlled-release solid dosage forms of mesalamine

 #270
20150037423
2015-02-05

ORALLY-DISINTEGRATING SOLID PREPARATION

 #271
20150037405
2015-02-05

PHARMACEUTICAL COMPOSITIONS OF LEVODOPA AND CARBIDOPA

 #272
20150030676
2015-01-29

STABLIZED MODIFIED RELEASE FOLIC ACID DERIVATIVE COMPOSITION, ITS THERAPEUTIC USE AND METHODS OF MANUFACTURE

 #273
20150024042
2015-01-22

PHASED DOSING OF CLOPIDOGREL

 #274
20150017241
2015-01-15

Oral formulations of deferasirox

 #275
20140377352
2014-12-25

Abuse resistant forms of extended release morphine, method of use and method of making

 #276
20140370083
2014-12-18

5-aminosalicyclic acid capsule formulation

 #277
20140350018
2014-11-27

Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects

 #278
20140348914
2014-11-27

Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof

 #279
20140335181
2014-11-13

Dry coated tablet

 #280
20140328913
2014-11-06

Rapidly disintegrating gelatinous coated tablets

 #281
20140328908
2014-11-06

Milrinone controlled-release formulation

 #282
20140322312
2014-10-30

Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient

 #283
20140314846
2014-10-23

MULTIPLE UNIT PHARMACEUTICAL FORMULATION

 #284
20140314842
2014-10-23

Carbidopa/levodopa gastroretentive drug delivery

 #285
20140309198
2014-10-16

METHOD OF TREATING ACNE

 #286
20140308359
2014-10-16

Easily dosable solid preparation

 #287
20140302134
2014-10-09

Formulation for the controlled release of one or several substances in the digestive tract of a mammal

 #288
20140296309
2014-10-02

Modified release compositions of epalrestat or a derivative thereof and methods for using the same

 #289
20140271887
2014-09-18

Antiemetic extended release solid dosage forms

 #290
20140271859
2014-09-18

Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability

 #291
20140271857
2014-09-18

Benzonatate modified release solid tablets and capsules

 #292
20140248350
2014-09-04

Delayed release film coatings containing calcium silicate and substrates coated therewith

 #293
20140248344
2014-09-04

Abuse resistant forms of extended release morphine, method of use and method of making

 #294
20140248343
2014-09-04

Abuse resistant forms of extended release morphine, method of use and method of making

 #295
20140242168
2014-08-28

SWELLABLE COATED TABLET

 #296
20140242162
2014-08-28

PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN

 #297
20140212461
2014-07-31

Methods for treatment of attention deficit hyperactivity disorder

 #298
20140199469
2014-07-17

SUSTAINED-RELEASE TABLET AND PROCESS FOR PREPARING THE SAME

 #299
20140193498
2014-07-10

Compositions and Methods for Treating Metabolic Disorders

 #300
20140180224
2014-06-26

Composition, device and method for delayed and sustained release of brain energy molecules